Gene-edited liver transplant to lower rejection risk
Part of Cancer, Digestive system clinical trials.
This trial tests a liver transplant using a donor organ that has been gene-edited to reduce the risk of rejection. It may help people who need a liver transplant and are not a perfect tissue match with their donor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 16 and 85 years old.
- You have end-stage liver disease or acute liver failure and are on the waiting list for a liver transplant.
- You will receive a donor liver that is not a perfect tissue match (this is typical for most liver transplants).
- You are healthy enough for surgery and can take standard anti-rejection medicines.
- You are willing to have extra biopsies and blood tests for long-term follow-up.
- You are not pregnant, breastfeeding, or needing a transplant of another organ at the same time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether using an “ex vivo perfusion” process—keeping a donor liver alive outside the body before transplant—can improve outcomes for certain people who need a liver transplant but have limited options. It may help patients who are too high-risk for standard transplant timing or options, including some cancer-related liver disease cases.
This trial studies liver transplantation for certain people with colorectal cancer that has spread only to the liver and cannot be removed with surgery. It aims to improve outcomes for carefully selected patients whose cancer is controlled on chemotherapy and who meet specific safety and scan requirements.
This study tests whether a special way of moving blood through the donor abdomen before surgery can improve liver (and other organ) transplant quality. It may help because doctors can check how well the liver seems to be working before it’s actually used.
This trial tests a specially edited donor kidney designed to reduce the chance of rejection, especially for people with high sensitivity to donor kidneys. If it works, it could make more kidneys available for those who have a hard time finding a match.
This trial tests a new treatment that uses your own blood stem cells, edited with CRISPR technology, to reduce or eliminate the need for blood transfusions in people with beta-thalassemia.
This early-phase study tests a gene-editing approach that turns off CD33 in donated blood-forming cells, aiming to make CD33-targeted immunotherapy safer and more effective. It is for adults with AML that came back after an allogeneic (donor) stem-cell transplant.
Hear when a new Liver Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.